The United Kingdom has a strong biotechnology industry, with companies working on advanced medicines, genetic research, vaccines, cell and gene therapies, and treatments for rare diseases. British biotech firms also collaborate with universities, hospitals, and pharmaceutical companies to develop new approaches to healthcare.

The following list highlights 10 notable biotechnology companies operating in the UK, considering their research, technologies, therapeutic focus, and contributions to the life sciences industry. It is not a strict ranking by revenue or company size.

1. AstraZeneca

AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, England. It was formed in 1999 through the merger of the Swedish company Astra AB and the British company Zeneca Group. Since then, it has grown into a major pharmaceutical and biotechnology business with research, manufacturing, and commercial operations across numerous countries. The company focuses on discovering, developing, manufacturing, and commercialising prescription medicines for serious and long-term diseases. Its research combines molecular biology, genomics, immunology, clinical science, and advanced drug development to create treatments for patients with complex medical needs.

AstraZeneca’s research portfolio covers several major therapeutic areas. In oncology, it develops medicines designed to target cancer cells and specific biological pathways involved in tumour growth. Its cardiovascular, renal, and metabolic research addresses conditions such as heart disease, kidney disease, and diabetes. The company also works in respiratory medicine, immunology, and rare diseases, where scientific research can help identify new treatment options for patients with limited alternatives. Its approach increasingly incorporates precision medicine, which aims to match treatments to the biological characteristics of a disease or patient.

The company’s established medicines include Tagrisso for certain types of lung cancer, Imfinzi for specific cancers, Farxiga for selected cardiovascular, kidney, and metabolic indications, Lynparza for certain cancers, and Fasenra for severe eosinophilic asthma and other approved indications. These products illustrate how different branches of biotechnology and pharmaceutical research can lead to medicines that work through distinct biological mechanisms. The approved uses of each product depend on the relevant country’s regulatory authorisations and prescribing guidance.

AstraZeneca also invests substantially in research and development, clinical trials, and partnerships with universities, biotechnology startups, and research institutions. These collaborations help it investigate new drug targets, test potential treatments, and develop technologies that may improve the discovery process. Its global scale gives it the resources to support programmes from early laboratory research through to large clinical trials and commercial manufacturing. AstraZeneca reported total revenue of approximately US$58.7 billion for 2025, reflecting its position as a major global biopharmaceutical business. Its combination of established medicines and ongoing research makes it an important contributor to the UK’s life sciences industry.

Company	AstraZeneca PLC
Brand	AstraZeneca
Business	A global biopharmaceutical company headquartered in Cambridge, UK, that discovers, develops, and commercialises prescription medicines for cancer, cardiovascular and metabolic diseases, respiratory conditions, immunology, and rare diseases.
FY2025 Revenue	US$58.739 billion in total revenue, an increase of 9% compared with 2024.
Major Products	Tagrisso, Imfinzi, Farxiga, Lynparza, Fasenra, and Symbicort.

2. GSK

GSK plc, formerly known as GlaxoSmithKline, is a British biopharmaceutical company headquartered in London, England. The company has a long history in pharmaceutical research and vaccine development and operates internationally through research facilities, manufacturing sites, and commercial offices. GSK focuses on discovering, developing, manufacturing, and supplying medicines and vaccines that prevent or treat diseases. Its scientific work combines immunology, microbiology, molecular biology, genetics, and clinical research to understand how diseases develop and how the body’s immune system can be used to prevent or control them. The company has a particularly strong presence in vaccines, infectious diseases, HIV, respiratory medicine, and selected cancers.

One of GSK’s most important areas is vaccine research. Vaccines help the immune system recognise specific pathogens or disease-related targets, allowing the body to respond more effectively when exposed to them. GSK develops vaccines for several infectious diseases, including shingles, respiratory syncytial virus, and meningococcal disease. Its products include Shingrix, a shingles vaccine; Arexvy, an RSV vaccine for eligible adults; and Bexsero, a vaccine against meningococcal group B disease. The company also develops specialty medicines for chronic and complex conditions, including certain respiratory disorders, immune-related diseases, and cancers.

GSK’s HIV business is another important part of its operations. The company develops medicines designed to suppress the virus and help patients manage HIV over the long term. Products such as Dovato are used in specific HIV treatment settings, while its broader research programmes investigate new ways to prevent and treat infectious diseases. In respiratory medicine, GSK develops treatments for conditions such as asthma and chronic obstructive pulmonary disease. Its research also includes oncology and immunology, where scientists study how biological pathways influence disease and how medicines can modify those pathways.

The company’s business extends beyond research to large-scale pharmaceutical manufacturing, quality control, regulatory compliance, and global distribution. Vaccine production is particularly complex because products must meet stringent safety, stability, and manufacturing standards. GSK collaborates with universities, biotechnology businesses, public health organisations, and clinical research centres to develop new medicines and improve existing treatments. It reported total turnover of approximately £32.7 billion for 2025. Through its vaccine portfolio, specialty medicines, and research pipeline, GSK remains a significant part of the UK’s pharmaceutical and biotechnology sector.

Company	GSK plc
Brand	GSK
Business	A British biopharmaceutical company headquartered in London, UK, that develops medicines and vaccines for infectious diseases, HIV, cancer, respiratory conditions, and immune-related disorders.
FY2025 Revenue	£32.667 billion in total turnover, representing 4% growth at actual exchange rates compared with 2024.
Major Products	Shingrix, Arexvy, Bexsero, Trelegy, Dovato, and Benlysta.

3. Isomorphic Labs

Isomorphic Labs is a London-based biotechnology company that applies artificial intelligence to drug discovery. It emerged from research associated with DeepMind and was established to use computational science to address difficult problems in biology and medicine. Traditional drug discovery often requires scientists to identify a biological target, screen thousands or millions of candidate molecules, conduct laboratory experiments, and gradually determine which candidates may be suitable for further development. Isomorphic Labs aims to improve parts of this process by using AI models to predict biological structures, understand molecular interactions, and support the design of potential drug candidates.

A central area of its work is computational biology. Proteins perform many essential functions in living organisms, and changes in their structure or behaviour can contribute to disease. Understanding the shape of a protein and how it interacts with other molecules can help researchers identify ways to influence its activity. AI-based systems can analyse biological data and generate predictions that help scientists prioritise experiments. These predictions do not automatically prove that a proposed medicine will work, but they can provide useful starting points for laboratory testing and further research.

Isomorphic Labs focuses on applying these capabilities to drug discovery across different therapeutic areas. Rather than concentrating exclusively on one disease, the company aims to build technology that can be used to investigate multiple biological targets and develop potential treatments. Its work involves computational modelling, molecular design, structural biology, and collaboration with scientists who understand the practical requirements of drug development. AI can help researchers explore chemical possibilities and reduce some inefficiencies in early-stage discovery, although candidates still need to demonstrate safety and effectiveness through experimental studies and clinical trials.

The company’s business model centres on its drug discovery platform, research programmes, and collaborations with pharmaceutical partners. These partnerships can combine AI-based discovery capabilities with the clinical development, manufacturing, and regulatory expertise of established drug companies. Isomorphic Labs represents a growing category of biotechnology businesses in which software and computational models are central to scientific research. Its longer-term impact will depend on whether AI-designed candidates can progress successfully through testing and become useful medicines.

Company	Isomorphic Labs
Brand	Isomorphic Labs
Business	A London-based AI-driven drug discovery company founded in 2021 as a spin-off from Google DeepMind. It uses artificial intelligence, machine learning, and computational biology to design potential medicines and accelerate drug discovery.
FY2025 Revenue	Not publicly disclosed in verified company reporting. The company raised US$600 million in March 2025 and announced a further US$2.1 billion Series B funding round in May 2026; funding is not revenue.
Major Products	IsoDDE (AI drug design engine), AI-powered molecular modelling, protein and drug-target prediction, and computational drug discovery programmes.

4. Autolus Therapeutics

Autolus Therapeutics is a biotechnology company associated with London, England, that develops engineered T-cell therapies for serious diseases, particularly certain blood cancers. Its research focuses on a form of treatment known as chimeric antigen receptor T-cell therapy, commonly called CAR-T therapy. T cells are immune cells that help the body recognise and respond to threats. In CAR-T treatment, a patient’s T cells are collected and modified so that they express a receptor designed to recognise a particular target on diseased cells. The modified cells are then prepared for administration to the patient, where they may identify and attack cells carrying the target.

Developing CAR-T treatments requires expertise across cell biology, genetic engineering, clinical medicine, and specialised manufacturing. The company works on engineering immune cells to recognise specific cancer markers and trigger an immune response. Its research also explores how the design of these cells may affect their activity, persistence, and ability to target disease. These characteristics are important because engineered cell therapies must be sufficiently active against cancer while also being managed carefully for safety. CAR-T treatments can cause serious side effects, including potentially severe immune reactions, and therefore require specialist medical assessment and monitoring.

Autolus has developed AUCELLO, also known as obecabtagene autoleucel, a CAR-T therapy associated with treatment for certain patients with B-cell acute lymphoblastic leukaemia. Product branding, regulatory status, and approved indications can vary by jurisdiction, so current prescribing and regulatory information should be consulted when describing its clinical use. The company also maintains research and development programmes investigating additional engineered cell therapies. These programmes are intended to explore new targets and potentially broaden the range of diseases that cell therapy may address.

The company’s activities extend from laboratory research and cell engineering to clinical trials, regulatory submissions, and manufacturing processes suitable for complex biological products. Unlike conventional tablets that can often be manufactured in large batches, many cell therapies involve highly specialised procedures and patient-specific treatment pathways. Autolus must therefore address both the scientific challenge of developing effective treatments and the operational challenge of producing them consistently. Its work is part of the wider UK advanced therapy sector, which includes organisations researching cell therapies, gene therapies, and other treatments based on living cells or genetic material.

Company	Autolus Therapeutics plc
Brand	Autolus Therapeutics
Business	A UK-based biopharmaceutical company developing programmed T-cell therapies for cancer and autoimmune diseases. It specialises in CAR-T cell therapy, which modifies immune cells to recognise and attack specific disease targets.
FY2025 Revenue	US$75.4 million in total revenue, including US$74.3 million in net product revenue from AUCATZYL and approximately US$1.1 million in licensing revenue.
Major Products	AUCATZYL (obecabtagene autoleucel), a CAR-T cell therapy approved for certain adults with relapsed or refractory B-cell acute lymphoblastic leukaemia; investigational cell therapies for cancer and autoimmune diseases.

5. Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company known for developing medicines based on a specialised class of molecules called bicyclic peptides. These molecules are engineered to form constrained structures that can bind to selected biological targets. Peptides are made from chains of amino acids, the same basic building blocks used in proteins, but their size and structure can differ substantially from those of large therapeutic proteins. Bicycle Therapeutics uses its proprietary technology to design peptides that may combine selected characteristics of conventional small-molecule drugs and larger biologic medicines.

The company’s research is particularly relevant to targeted cancer treatments. Cancer cells can display specific proteins or molecular features that researchers may be able to use as targets for treatment. Bicycle Therapeutics investigates peptides that bind to such targets and explores ways to use them in therapeutic programmes. Some approaches involve attaching a targeting molecule to a drug payload, with the aim of directing treatment towards particular cells. This type of drug conjugate research requires careful investigation of target recognition, drug delivery, biological activity, and potential side effects.

A key element of the company’s work is its peptide discovery platform. Researchers use molecular design, screening, and laboratory testing to identify candidates with desirable properties. The resulting molecules must then undergo further evaluation to determine how they behave in the body, whether they reach the intended target, and whether they have an acceptable safety profile. Although engineered peptides offer interesting possibilities, each candidate must demonstrate its own performance through preclinical studies and clinical trials. The company’s research therefore combines biotechnology, chemistry, pharmacology, and drug development.

Bicycle Therapeutics operates through its own research and development programmes and can collaborate with pharmaceutical companies interested in its technology. Partnerships can help provide additional resources and expertise for advancing drug candidates. Its work demonstrates how biotechnology companies can specialise in a particular molecular platform rather than attempting to develop medicines across every therapeutic area. By developing engineered peptides for targeted treatments, Bicycle Therapeutics contributes to research into new ways of delivering medicines and interacting with disease-related biological targets.

Company	Bicycle Therapeutics plc
Brand	Bicycle Therapeutics
Business	A clinical-stage biotechnology company headquartered in Cambridge, UK, that develops medicines using specially engineered bicyclic peptides. Its research focuses on targeted cancer treatments and other therapies designed to interact with specific biological targets.
FY2025 Revenue	US$72.6 million in collaboration revenue, primarily from research and development partnerships. The company had no approved products generating sales in 2025.
Major Products	Zelenectide pevedotin (Nectin-4-targeted investigational therapy), nuzefatide pevedotin (EphA2-targeted investigational therapy), and its proprietary Bicycle peptide drug discovery platform.

6. Silence Therapeutics

Silence Therapeutics is a biotechnology company focused on developing medicines using RNA interference, commonly known as RNAi. RNA interference is a natural biological process that can reduce the production of specific proteins by targeting messenger RNA. Messenger RNA carries instructions from genetic material to the cellular machinery responsible for making proteins. In RNAi-based medicine, scientists design small interfering RNA molecules, known as siRNA, to recognise selected messenger RNA sequences and help the cell break them down. This can reduce production of the protein associated with a particular disease process.

The technology offers a different approach from medicines that act directly on proteins after they have been produced. If a disease is driven by an unwanted or excessive protein, reducing its production may help address the underlying biological mechanism. Silence Therapeutics develops RNA-based candidates designed to target specific genes and biological pathways. Its research has included cardiovascular and metabolic diseases, as well as other serious conditions where gene silencing may provide a useful therapeutic approach. The company also works on delivery technologies, which are essential because RNA molecules must reach the appropriate cells and tissues to have their intended effect.

Developing RNA medicines presents several scientific challenges. RNA molecules can be broken down in the body, may not naturally reach the desired tissues in sufficient quantities, and must be designed to target the intended sequence accurately. Researchers therefore need to investigate molecular stability, delivery, dosing, off-target effects, and safety. Advances in RNA chemistry and delivery systems have helped make RNA-based medicines a significant area of modern biotechnology, but each treatment still requires rigorous testing to establish its safety and effectiveness.

Silence Therapeutics advances its research through internal drug development programmes and collaborations with other pharmaceutical businesses. Such partnerships can combine the company’s RNAi expertise with additional capabilities in clinical development, manufacturing, and commercialisation. The company is part of a broader movement towards precision medicine, in which treatments are designed to influence specific biological mechanisms. Its work may create opportunities for conditions that have been difficult to treat with conventional medicines, although the clinical value of each candidate depends on the results of its development programme.

Company	Silence Therapeutics plc
Brand	Silence Therapeutics
Business	A clinical-stage biotechnology company headquartered in London, UK, that develops precision medicines using RNA interference (RNAi) technology to silence genes associated with disease. Its research focuses on rare and common diseases, including cardiovascular and blood disorders.
FY2025 Revenue	US$559,000 (approximately US$0.56 million), mainly from collaboration-related activities.
Major Products	Divesiran (investigational siRNA therapy for polycythaemia vera), zerlasiran (investigational therapy targeting lipoprotein(a)), and its proprietary mRNAi GOLD™ siRNA technology platform.

7. Immunocore

Immunocore is a biotechnology company headquartered in Abingdon, Oxfordshire, England. It specialises in immunotherapies based on engineered T-cell receptors. T cells are an important component of the immune system because they can recognise specific molecular signals associated with infected or abnormal cells. However, many cancer cells can evade immune detection, and some cancer-related targets are difficult to address using conventional antibody-based treatments. Immunocore develops engineered proteins designed to recognise selected protein fragments presented on cell surfaces and direct T cells towards cells displaying those targets.

Its technology platform is designed to bring together target recognition and immune-cell activation. A therapeutic molecule can bind to a specific protein fragment presented by a cell and help recruit T cells to respond against that cell. This approach requires detailed knowledge of the target, the way it is presented by cells, and the immune response that follows. Researchers must also consider patient eligibility, safety, and the possibility of unintended immune reactions. The company’s work combines protein engineering, immunology, molecular biology, and clinical research.

One of Immunocore’s best-known products is KIMMTRAK, also called tebentafusp. It is used for eligible patients with a particular type of metastatic uveal melanoma, a cancer that begins in the eye. The treatment works through a specialised immune-targeting mechanism and is authorised for specific patient groups in relevant markets. Immunocore also investigates other therapeutic candidates, including programmes involving cancer and additional disease areas. The existence of an investigational programme does not mean that the treatment has been proven effective or approved for use.

Immunocore’s activities include research, clinical development, regulatory work, and commercialisation of approved therapies. It collaborates with clinical centres and research partners to investigate new targets and improve understanding of how engineered immune therapies can be used. Its work highlights the role of biotechnology in creating treatments that interact with the immune system in highly targeted ways. By developing engineered T-cell receptor therapies, Immunocore contributes to the broader field of precision immunotherapy, where treatment design is guided by specific molecular features of a disease.

Company	Immunocore Holdings plc
Brand	Immunocore
Business	A UK-based commercial-stage biotechnology company headquartered in Abingdon, Oxfordshire. It develops immunotherapies using engineered T-cell receptors to target cancer and other diseases.
FY2025 Revenue	US$400.016 million in total revenue, primarily from sales of KIMMTRAK, an increase of approximately 29% compared with 2024.
Major Products	KIMMTRAK (tebentafusp) for eligible patients with metastatic uveal melanoma; brenetafusp, an investigational cancer therapy; and other investigational programmes targeting cancer, HIV, and autoimmune diseases.

8. CellCentric

CellCentric is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research explores the role of gene regulation in disease, particularly the activity of proteins known as p300 and CBP. These proteins help regulate how genetic information is used by cells and influence the activity of various genes. In certain cancers, changes in gene regulation can support the survival or growth of malignant cells. CellCentric investigates whether inhibiting these proteins can disrupt disease-related processes and provide a new treatment strategy.

The company’s research is part of a wider field known as epigenetics and gene regulation. Not every change in cellular behaviour results from a mutation in the DNA sequence itself; changes in the way genes are switched on or off can also affect how cells function. By studying proteins involved in this regulation, scientists aim to identify vulnerabilities that could be targeted with medicines. CellCentric’s approach requires researchers to understand how the target proteins influence cancer biology, whether a candidate can inhibit them effectively, and how this activity affects both cancer cells and healthy tissues.

Inobrodib is the company’s prominent investigational drug candidate. It is an oral small-molecule inhibitor of p300 and CBP that has been studied in cancer programmes, including multiple myeloma. The purpose of clinical studies is to assess how the candidate behaves in patients, what dose may be appropriate, what side effects occur, and whether meaningful clinical benefits can be demonstrated. As an investigational medicine, inobrodib should not be presented as an established treatment available for general use unless the relevant regulatory approval has been confirmed.

CellCentric’s business activities focus on advancing its drug candidates through research and clinical development. This includes working with investigators, conducting trials, evaluating data, and determining the next steps for development. Smaller biotechnology companies often concentrate on one or a few scientific approaches, allowing them to build specialised expertise around a particular disease mechanism. CellCentric follows this model by focusing on cancer biology and targeted drug development. Its research contributes to the search for treatments that act on specific processes involved in the development and progression of cancer.

Company	CellCentric Limited
Brand	CellCentric
Business	A privately held, clinical-stage biotechnology company founded in Cambridge, UK, that develops innovative cancer treatments. Its main focus is inobrodib, an oral drug designed to inhibit the p300/CBP proteins involved in gene regulation and cancer development.
FY2025 Revenue	Not publicly disclosed as a verified standalone revenue figure. CellCentric raised US$120 million in Series C funding in May 2025; funding is not revenue.
Major Products	Inobrodib, an investigational oral cancer drug being studied primarily for multiple myeloma, and its p300/CBP inhibitor drug development programme.

9. Oxford Nanopore Technologies

Oxford Nanopore Technologies is a life sciences technology company headquartered in Oxford, England. It develops DNA and RNA sequencing platforms that allow researchers to analyse genetic material. Sequencing is the process of determining the order of nucleotides in DNA or RNA, providing information that can help scientists study genes, genetic variation, disease-causing organisms, and biological processes. Oxford Nanopore uses a technology in which molecules pass through extremely small pores, producing changes in electrical signals that can be interpreted to determine their sequence.

One of the company’s distinguishing features is its range of sequencing systems, which includes portable devices as well as platforms designed for higher-throughput work. MinION is a compact sequencing device, while GridION and PromethION systems support different research and laboratory requirements. The company also supplies flow cells, consumables, software, and data-analysis tools that help users process and interpret sequencing information. These products are used in a range of research environments, including university laboratories, biotechnology companies, genomic studies, and infectious disease investigations.

Oxford Nanopore’s technology supports several applications. In genomics, researchers can examine genetic differences and investigate how variations may relate to biological traits or diseases. In infectious disease research, sequencing can help scientists characterise pathogens and investigate their genetic relationships. RNA sequencing can provide information about gene expression and the molecules being produced by cells. Depending on the system and research design, sequencing data can also help researchers study complex genetic regions and investigate biological changes over time.

Unlike a conventional pharmaceutical company, Oxford Nanopore primarily provides tools and technology rather than developing a broad portfolio of medicines. Its commercial model includes selling instruments, consumables, software, and related services. Sequencing results must be interpreted carefully, and clinical applications require appropriate validation and regulatory compliance. Nevertheless, the company’s technology supports the wider biotechnology industry by giving researchers access to detailed genetic information. Its contribution is especially relevant as genomics becomes increasingly important in biomedical research, drug development, public health, and precision medicine.

Company	Oxford Nanopore Technologies plc
Brand	Oxford Nanopore Technologies
Business	A UK-based life sciences technology company headquartered in Oxford, England. It develops nanopore-based DNA and RNA sequencing technology used in genomics, biomedical research, infectious disease analysis, and drug discovery.
FY2025 Revenue	£223.9 million, an increase of 22.2% compared with 2024.
Major Products	MinION, GridION, PromethION, sequencing flow cells, DNA and RNA sequencing kits, and data-analysis software.

10. bit.bio

bit.bio is a biotechnology company based in Cambridge, England, that develops technologies for producing defined human cell types. Its work is rooted in synthetic biology, a field that uses engineered biological systems to achieve specific functions. In biomedical research, scientists often need particular human cells to study how diseases develop, investigate the effects of medicines, or test scientific hypotheses. Obtaining consistent and reliable cell models can be difficult, so bit.bio aims to make selected cell types available through its cell-programming technology.

The company uses a technology called opti-ox, which applies programmed gene expression to convert stem cells into specific cell identities. Stem cells have the potential to develop into different cell types, but guiding this process consistently requires control over the genes that influence cell identity. By programming these processes, bit.bio seeks to produce defined human cells with more consistent characteristics for research applications. These cells can help researchers study biological systems under controlled laboratory conditions and reduce some of the variability that can occur between experiments.

Its ioCells range includes cell types designed for use in research, including applications involving neuroscience and other areas of biomedical science. Researchers can use these cells to investigate cellular behaviour, model aspects of disease, and evaluate potential medicines. For example, scientists studying neurological disorders may require specific types of human neurons, while researchers developing treatments may need suitable cellular models to test how a candidate affects a biological process. The usefulness of any cell model depends on how closely it represents the biological conditions being studied.

bit.bio’s contribution is different from that of a company that develops and sells approved medicines. It supplies research tools and cell technologies that can support work performed by universities, pharmaceutical companies, biotechnology businesses, and laboratories. The company operates at the intersection of stem cell biology, genetic programming, and synthetic biology. By seeking to make specialised human cell types more accessible and reproducible, bit.bio aims to support drug discovery and biomedical research. Its technology may help researchers improve the quality of laboratory studies, although findings from cell models still require further validation before they can be applied to patients.

Company	bit.bio Limited
Brand	bit.bio
Business	A Cambridge-based synthetic biology company founded in 2016. It develops technologies to programme human stem cells into specific cell types for biomedical research, drug discovery, and potential cell therapies.
FY2025 Revenue	Not publicly disclosed in verified company reporting.
Major Products	ioCells research cell products, ioDisease Model Cells, CRISPR-Ready ioCells, ioTracker Cells, and its proprietary opti-ox™ cell-programming technology.

Why the UK is important for biotechnology

The UK benefits from established research universities, specialised life sciences clusters, clinical research infrastructure, and collaboration between academic institutions and commercial companies. Cambridge, Oxford, London, and other regional centres support biotechnology research, startup formation, and the development of new medicines.

The sector includes both large global companies and smaller specialist firms. Some develop and sell approved medicines, while others focus on experimental treatments or provide technologies that support the wider research industry.

Conclusion

These ten companies represent different parts of the UK’s biotechnology ecosystem. AstraZeneca and GSK develop and commercialise medicines on a global scale, while companies such as Autolus Therapeutics, Immunocore, Silence Therapeutics, and Bicycle Therapeutics focus on specialised therapeutic technologies.

Isomorphic Labs explores the role of AI in drug discovery, Oxford Nanopore Technologies provides tools for genetic analysis, and bit.bio supplies programmed human cells for research. CellCentric focuses on investigational cancer treatments.

Together, they illustrate how biotechnology extends beyond manufacturing medicines: it also includes the computational systems, molecular tools, cellular platforms, and scientific research needed to develop future treatments.

Frequently Asked Questions

1. What are the top biotechnology companies in the UK?

Some notable biotechnology and biopharmaceutical companies in the UK include AstraZeneca, GSK, Isomorphic Labs, Autolus Therapeutics, Bicycle Therapeutics, Silence Therapeutics, Immunocore, CellCentric, Oxford Nanopore Technologies, and bit.bio. These companies work across medicine development, genetic research, AI-driven drug discovery, and advanced biotechnology.

2. What is the main purpose of biotechnology companies?

Biotechnology companies use biological systems, cells, genes, and scientific technologies to develop products and solutions. Their work includes creating medicines and vaccines, researching treatments for diseases, analysing genetic information, and developing tools for medical and laboratory research.

3. Which UK biotech companies specialise in pharmaceutical research?

AstraZeneca and GSK are major biopharmaceutical companies that develop and commercialise medicines. Other companies, including Bicycle Therapeutics, Immunocore, Autolus Therapeutics, and CellCentric, focus on specialised therapeutic technologies and drug development programmes.

4. Which UK biotechnology companies focus on cancer treatment?

AstraZeneca, GSK, Autolus Therapeutics, Bicycle Therapeutics, Immunocore, and CellCentric conduct research related to cancer. Their approaches include targeted medicines, immunotherapy, engineered cell treatments, and investigational drugs designed to interfere with specific biological processes.

5. How is artificial intelligence used in biotechnology?

Artificial intelligence can help researchers analyse biological data, predict molecular structures, identify potential drug targets, and design candidate molecules. Isomorphic Labs is an example of a UK-based company applying AI to drug discovery. AI-generated predictions still require laboratory testing and clinical evaluation.

6. What is the role of genetic research in biotechnology?

Genetic research helps scientists understand how genes influence biological functions, inherited conditions, and disease development. Oxford Nanopore Technologies provides DNA and RNA sequencing tools, while Silence Therapeutics develops medicines that use RNA interference to reduce the production of selected proteins.

7. How do biotechnology companies develop new medicines?

Medicine development usually begins with laboratory research and the identification of a potential biological target. Researchers then develop candidate treatments, conduct preclinical testing, and evaluate suitable candidates in clinical trials. Regulatory authorities assess the evidence before a medicine can be approved for use.

8. Why is the UK an important centre for biotechnology?

The UK has established universities, scientific research institutions, specialist laboratories, clinical research facilities, and collaborations between academic researchers and commercial companies. Cambridge, Oxford, and London are important centres for biotechnology, pharmaceutical research, and life sciences businesses.

9. What is the difference between biotechnology and pharmaceutical companies?

Biotechnology companies often use cells, genes, proteins, or other biological systems to develop products and technologies. Pharmaceutical companies focus on discovering, developing, manufacturing, and selling medicines. The two sectors overlap considerably, as many modern pharmaceutical companies use biotechnology in their research and development.

10. What is the future of the UK biotechnology industry?

The UK biotechnology industry is exploring AI-powered drug discovery, precision medicine, RNA-based treatments, cell and gene therapies, genomics, and synthetic biology. Future progress will depend on scientific discoveries, clinical trial results, investment, regulatory approvals, and the ability to turn research into effective products.